%0 Journal Article %T Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? %A Metro, Giulio %A Di Maio, Massimo %J Translational Lung Cancer Research %D 2018 %B 2018 %9 %! Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? %K %X We agree with dr. Addeo and dr. Banna when they emphasize that the biology of non-small cell lung cancer (NSCLC) is complex, and that a single biomarker is probably not exhaustive in order to optimally predict (either positively or negatively) the potential efficacy of immune checkpoint inhibitors. %U https://tlcr.amegroups.org/article/view/23045 %P S294-S296 %@ 2226-4477